title: A study on the role of nitric oxide and iron in 3-morpholino-sydnonimine-induced increases in dopamine release in the striatum of freely moving rats.
abstract: 1. We showed previously that interaction between NO and iron (II), both released following the decomposition of sodium nitroprusside (SNP), accounted for the late SNP-induced dopamine (DA) increase in dialysates from the striatum of freely moving rats; in addition, we showed that co-infusion of iron (II) with the NO-donor S-nitroso-N-acetylpenicillamine mimicked SNP effects on striatal DA release. 2. In the present study, intrastriatal co-infusion of iron (II) (given as FeSO(4), 1 mM for 40 min) with the NO-donor and potential peroxynitrite generator 3-morpholinosydnonimine (SIN-1) (0.2, 0.5, 1.0 or 5.0 mM for 180 min), potentiated the SIN-1-induced increase in DA concentration in dialysates from the striatum of freely moving rats. Neither alone nor associated with iron (II) did SIN-1 induce changes in dialysate ascorbic acid or uric acid concentrations. 3. Neither co-infusion of a superoxide dismutase mimetic nor uric acid affected SIN-1-induced increases in dialysate DA concentration. 4. Infusion of the iron chelator deferoxamine (0.2 mM for 180 min) decreased dialysate DA and attenuated SIN-1-induced increases in dialysate DA concentrations. 5. These results suggest that iron plays a key role in SIN-1-induced release of striatal DA and do not support any role for either peroxynitrite or superoxide anion in SIN-1-induced release of striatal DA.
authors.affiliation: Department of Pharmacology, University of Sassari, viale S. Pietro 43B, 07100 Sassari, Italy.
authors.forename: P A
authors.initials: PA
authors.lastname: Serra
authors.forename: G
authors.initials: G
authors.lastname: Rocchitta
authors.forename: G
authors.initials: G
authors.lastname: Esposito
authors.forename: M R
authors.initials: MR
authors.lastname: Delogu
authors.forename: R
authors.initials: R
authors.lastname: Migheli
authors.forename: E
authors.initials: E
authors.lastname: Miele
authors.forename: M S
authors.initials: MS
authors.lastname: Desole
authors.forename: M
authors.initials: M
authors.lastname: Miele
mesh_terms: D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000111:Acetylcysteine / Q000494:pharmacology; D000818:Animals; D001205:Ascorbic Acid / Q000378:metabolism; D003342:Corpus Striatum / Q000187:drug effects* / Q000378:metabolism; D003676:Deferoxamine / Q000494:pharmacology; D015314:Dialysis Solutions / Q000737:chemistry; D004298:Dopamine / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D016166:Free Radical Scavengers / Q000494:pharmacology; D006719:Homovanillic Acid / Q000378:metabolism; D007501:Iron / Q000494:pharmacology*; D008297:Male; D008665:Metalloporphyrins / Q000494:pharmacology; D008981:Molsidomine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D009068:Movement; D009569:Nitric Oxide / Q000502:physiology*; D020030:Nitric Oxide Donors / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D014527:Uric Acid / Q000378:metabolism / Q000494:pharmacology
chemical_list: D015314:Dialysis Solutions; D016166:Free Radical Scavengers; D008665:Metalloporphyrins; D020030:Nitric Oxide Donors; C097284:manganese(III)-tetrakis(4-benzoic acid)porphyrin; D015102:3,4-Dihydroxyphenylacetic Acid; D014527:Uric Acid; D009569:Nitric Oxide; C002385:linsidomine; D008981:Molsidomine; D007501:Iron; D003676:Deferoxamine; D001205:Ascorbic Acid; D004298:Dopamine; D000111:Acetylcysteine; D006719:Homovanillic Acid